2020 will be a milestone year for Asarina Pharma. Two phase 2 results are to be presented, and first up is the phase 2b results in their lead indication, premenstrual dysphoric disorder (PMDD). In this interview, CEO Peter Nordkild shares his views on the upcoming milestones.